Omega Diagnostics Group (ODX) Earns Corporate Rating from FinnCap

Omega Diagnostics Group (LON:ODX)‘s stock had its “corporate” rating restated by analysts at FinnCap in a research report issued to clients and investors on Wednesday, ThisIsMoney.Co.Uk reports.

Shares of ODX stock opened at GBX 11.75 ($0.15) on Wednesday. The firm has a market capitalization of $14.92 million and a P/E ratio of -2.26. The company has a quick ratio of 1.18, a current ratio of 1.82 and a debt-to-equity ratio of 3.80. Omega Diagnostics Group has a 1 year low of GBX 8.50 ($0.11) and a 1 year high of GBX 18 ($0.24).

Omega Diagnostics Group Company Profile

Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases.

Read More: What are gap-down stocks?

Receive News & Ratings for Omega Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit